Results 81 to 90 of about 18,181 (226)

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America

open access: yesNeurology and Therapy, 2019
The use of biosimilar drugs for multiple sclerosis (MS) has become widespread in Latin America, with the goal of reducing costs of treatments, promoting the sustainability of healthcare systems, and improving patient access to these therapies.
Judith Steinberg   +14 more
doaj   +1 more source

Real‐World Outcomes of Rituximab in Pemphigus: An Australian Tertiary Cohort

open access: yesAustralasian Journal of Dermatology, EarlyView.
ABSTRACT Rituximab is endorsed internationally as first‐line therapy for moderate‐to‐severe pemphigus, but Australian guidelines position it as a rescue agent and local outcome data are limited. In this single‐centre retrospective cohort, 24 adults with pemphigus vulgaris (n = 16) or pemphigus foliaceus (n = 8) received rituximab as part of routine ...
Pokphazz Christjaroon   +4 more
wiley   +1 more source

Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study [PDF]

open access: yes
Debdulal Chakraborty,1 Tushar Kanti Sinha,1 Sourav Sinha,2 Rupak Kanti Biswas,2 Aniruddha Maiti,3 Krishnendu Nandi,2 Dinesh Rungta,1 Ranabir Bhattacharya1 1Vitreo-Retina Services, Disha Eye Hospitals, Kolkata, WB, India; 2Vitreo-retina Services ...
Nandi K   +7 more
core  

Beyond Nature's Blueprint: Macrocyclic Peptides Containing Unnatural Amino Acids in Therapeutic Development

open access: yesAngewandte Chemie, Volume 138, Issue 45, 2 November 2026.
Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma   +5 more
wiley   +2 more sources

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Pharmacovigilance, traceability and building trust in biosimilar medicines

open access: yes, 2017
The Medicines for Europe's Biosimilar Medicines Group met at the 2017 European Association of Hospital Pharmacists conference in France to discuss pharmacovigilance, traceability and building trust in biosimilar ...
Teun van Gelder   +5 more
core   +1 more source

Comparative study: Demographic variables (branded enoxaparin vs biosimilar enoxaparin groups).

open access: yes, 2023
Comparative study: Demographic variables (branded enoxaparin vs biosimilar enoxaparin groups).
Chadli Dziri (14048856)   +7 more
core   +1 more source

A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy

open access: yesAboutOpen, 2020
Introduction: Granulocyte-colony stimulating factors (G-CSFs) can significantly reduce the risk of febrile neutropenia (FN) among certain patients receiving chemotherapy. FN is associated with significant clinical and nonclinical complications.
Roberto Ravasio   +3 more
doaj   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis   +4 more
wiley   +1 more source

Denosumab discontinuation and fracture risk: getting the balance right

open access: yesInternal Medicine Journal, EarlyView.
Abstract Denosumab is a highly effective therapy for osteoporosis. Since its approval by the Therapeutic Goods Administration (TGA) in 2010, use of denosumab has surged across Australia, delivering substantial fracture‐prevention benefits to tens of thousands of patients. However, stopping denosumab may lead to acute loss of bone with an increased risk
Albert S. Kim, Christian M. Girgis
wiley   +1 more source

Home - About - Disclaimer - Privacy